Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516159 | 1.00 | CHRM1 (0.56) | CHRM1LMNACHRM5CCNE2CCNE1 | |
| SCHEMBL7318731 | 0.88 | GABRA1 (0.54) | CHRM1LMNACCNE2CCNE1CDK2 | |
| SCHEMBL7304407 | 0.87 | OPRK1 (0.46) | CHRM1LMNACCNE2CCNE1CDK2 | |
| SCHEMBL7305491 | 0.87 | GABRA1 (0.43) | CHRM1LMNACHRM5GABRA1GABRA5 | |
| SCHEMBL7319802 | 0.84 | GABRA1 (0.41) | CHRM1LMNACHRM5TRPV1GABRA1 | |
| Hydrochloric Acid SCHEMBL7309472 | 0.83 | CHRM1 (0.52) | CHRM1LMNACCNE2CCNE1CDK2 | |
| SCHEMBL7312454 | 0.81 | LMNA (0.51) | CHRM1LMNATRPV1 | |
| SCHEMBL7305628 | 0.79 | LMNA (0.49) | CHRM1LMNATRPV1 | |
| SCHEMBL7314804 | 0.79 | LMNA (0.49) | CHRM1LMNATRPV1 | |
| SCHEMBL7305784 | 0.79 | CHRM1 (0.54) | CHRM1LMNACHRM5CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114292242-B | Synthesis method of midazolam intermediate | 宜昌天仁药业有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114292242-A | Synthesis method of midazolam intermediate | 宜昌天仁药业有限责任公司 | 2022-04-08 | — | — | CN | claimed |
| CN-114292242-B | Synthesis method of midazolam intermediate | 宜昌天仁药业有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114292242-B | Synthesis method of midazolam intermediate | 宜昌天仁药业有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114292242-A | Synthesis method of midazolam intermediate | 宜昌天仁药业有限责任公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114292242-A | Synthesis method of midazolam intermediate | 宜昌天仁药业有限责任公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-112028843-A | Preparation method of 7-chloro-5- (2-fluorophenyl) -3H-1, 4-benzodiazepine-2-methylamine | 北京益民药业有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-7776852-B2 | Process for producing highly pure midazolam and salts thereof | CHEMAGIS LTD. (IL) | 2010-08-17 | — | — | US | disclosed |
| US-7776852-B2 | Process for producing highly pure midazolam and salts thereof | CHEMAGIS LTD. (IL) | 2010-08-17 | — | — | US | disclosed |
| US-20090069306-A1 | PROCESS FOR PRODUCING HIGHLY PURE MIDAZOLAM AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2009-03-12 | — | — | US | disclosed |
| US-20090069306-A1 | PROCESS FOR PRODUCING HIGHLY PURE MIDAZOLAM AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2009-03-12 | — | — | US | disclosed |
| US-4347365-A | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4307237-A | ANTICONVULSANTS, SEDATIVES, MUSCLE RELAXANTS | HOFFMANN-LA ROCHE INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4280957-A | Imidazodiazepines and processes therefor | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-RE30473-E | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4166185-A | ANTICONVULSANTS, ANXIOLYTICS, SEDATIVES, MUSCLE RELAXANTS | HOFFMANN-LA ROCHE INC. (US) | 1979-08-28 | — | — | US | disclosed |
| US-4147875-A | ANTIDEPRESSANTS, ANTICONBULSANTS, MUSCLE RELAXANTS | HOFFMANN-LA ROCHE INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4146722-A | SEDATIVES, MUSCLE RELAXANTS, ANTICONVULSANTS | HOFFMANN-LA ROCHE INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4125726-A | SEDATIVES, MUSCLE RELAXANTS, ANXIOLYTICS, ANTICONVULSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4105852-A | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069306-A1 | PROCESS FOR PRODUCING HIGHLY PURE MIDAZOLAM AND SALTS THEREOF | CYP3A4, CYP3A43, CYP3A5 | CHRM1 423/4885LMNA 3599/4885CHRM5 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.